Selected historical chemotherapy studies for newly diagnosed older HL patients in advanced stages
| Reference . | N . | Therapy . | Outcomes . | Selected toxicities ≥ grade 3 . | TRM (%) . |
|---|---|---|---|---|---|
| Weekes et al4 | 31 | ChlVPP | 5-y EFS, 24% | NR | 13% |
| 5-y OS, 30% | |||||
| 25 | ChlVPP/ABV | 5-y EFS, 52% | 16% | ||
| 5-y OS, 67% | |||||
| Levis et al23 ,* | 57 | VEPEMB | 5-y RFS, 66% | Anemia (18%), infection (14%) | 3% |
| 5-y OS, 32% | |||||
| Ballova et al30,* | 26 | COPP/ABVD | 5-y HD-FFTF, 55% | Anemia (24%), thrombocytopenia (16%), infection (12%) | 8% |
| 5-y OS, 50% | |||||
| 42 | BEACOPP baseline | 5-y OS, 50% | Thrombocytopenia (49%), anemia (41%), infection (23%), cardiac (15%) | 21% | |
| Halbsguth et al45,* | 60 | BACOPP | 2-y PFS, 71% | Infection (23%), thrombocytopenia (22%) | 12% |
| 2-y OS, 76% | |||||
| Böll et al44,* | 59 | PVAG | 3-y PFS, 58% | Infection (22.8%), anemia (17.5%), thrombocytopenia (15.8%) | 2% |
| 3-y OS, 66% | |||||
| Proctor et al13,* | 72 | VEPEMB | CR, 61% | Neutropenic sepsis (15%), neutropenia (12%), myocardial infarction (2%) | 4% |
| 3-y PFS, 52% | |||||
| 3-y OS, 62% | |||||
| Evens et al10,* | 45 | ABVD and Stanford V | 5-y PFS, 48% | BLT (24%, primarily ABVD), gastrointestinal hemorrhage (5%, Stanford V only) | 9% |
| 5-y OS, 58% |
| Reference . | N . | Therapy . | Outcomes . | Selected toxicities ≥ grade 3 . | TRM (%) . |
|---|---|---|---|---|---|
| Weekes et al4 | 31 | ChlVPP | 5-y EFS, 24% | NR | 13% |
| 5-y OS, 30% | |||||
| 25 | ChlVPP/ABV | 5-y EFS, 52% | 16% | ||
| 5-y OS, 67% | |||||
| Levis et al23 ,* | 57 | VEPEMB | 5-y RFS, 66% | Anemia (18%), infection (14%) | 3% |
| 5-y OS, 32% | |||||
| Ballova et al30,* | 26 | COPP/ABVD | 5-y HD-FFTF, 55% | Anemia (24%), thrombocytopenia (16%), infection (12%) | 8% |
| 5-y OS, 50% | |||||
| 42 | BEACOPP baseline | 5-y OS, 50% | Thrombocytopenia (49%), anemia (41%), infection (23%), cardiac (15%) | 21% | |
| Halbsguth et al45,* | 60 | BACOPP | 2-y PFS, 71% | Infection (23%), thrombocytopenia (22%) | 12% |
| 2-y OS, 76% | |||||
| Böll et al44,* | 59 | PVAG | 3-y PFS, 58% | Infection (22.8%), anemia (17.5%), thrombocytopenia (15.8%) | 2% |
| 3-y OS, 66% | |||||
| Proctor et al13,* | 72 | VEPEMB | CR, 61% | Neutropenic sepsis (15%), neutropenia (12%), myocardial infarction (2%) | 4% |
| 3-y PFS, 52% | |||||
| 3-y OS, 62% | |||||
| Evens et al10,* | 45 | ABVD and Stanford V | 5-y PFS, 48% | BLT (24%, primarily ABVD), gastrointestinal hemorrhage (5%, Stanford V only) | 9% |
| 5-y OS, 58% |
The studies included a minimum of 25 patients.
ABV, adriamycin, bleomycin, vinblastine; BACOPP, bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; BLT, bleomycin lung toxicity; ChlVPP, chlorambucil, vinblastine, procarbazine, and prednisone; COPP, cyclophosphamide, vincristine, procarbazine, and prednisone; CR, complete remission; EFS, event-free survival; FFTF, freedom from treatment failure; HD, Hodgkin disease; NR, not reported; OS, overall survival; PFS, progression-free survival; PVAG, prednisone, vinblastine, doxorubicin, and gemcitabine; RFS, relapse-free survival; TRM, treatment-related mortality; VEPEMB, vinblastine, cyclophosphamide, procarbazine, etoposide, mitoxantrone, and bleomycin.
Prospective clinical study.